Journal of Viral Hepatitis · 2001 · 17 citations · 12 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyHepatic PharmacotherapyHepatitis PharmacotherapyAntiviral PharmacotherapyAntiviral TherapyInterferon ResponsesInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentAntiviral Therapy SelectionChronic Viral HepatitisCombination Antiviral RegimensDrug Resistance ManagementHepatitis C Virus GenotypeHepatitis C Virus ResistanceInterferon Alfa TherapySerum Alanine Aminotransferase
The optimal therapy for patients with chronic hepatitis C who have not responded to interferon (IFN) is still an unsolved issue. The aim of this study was to evaluate the efficacy and tolerability of a high dose of IFN-alpha2a plus amantadine for chronic hepatitis C patients who were non-responders to a previous course of IFN. Forty consecutive patients with chronic hepatitis C, genotype 1b, who had not responded to IFN-alpha, were randomized to receive: (i) IFN 4.5 MU daily plus amantadine 200 mg/day for 4 weeks and then IFN 6 MU thrice weekly plus amantadine 200 mg/day for an additional 5 months (group A) or (ii) IFN alone at the same dosage and duration (group B). After 1 month of therapy, normal alanine aminotransferase (ALT) values were observed in three of 21 (14.3%) patients in group A and in three of 19 (15.8%) in group B; serum hepatitis C virus (HCV)-RNA clearance was observed in one patient (4.8%) in group A and in six (31.6%) in group B. At the end of treatment, six patients (28.6%) in group A and three (15.8%) in group B had normal ALT levels; however, HCV-RNA in serum was detectable in all of them at levels comparable to the basal values; an ALT relapse occurred within 3 months of stopping therapy. The combination of daily IFN plus amantadine was ineffective in this setting.
12
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Avidan U. Neumann, Nancy P. Lam, Harel Dahari et al. · Science · 1998 · 2.1K citations
Ribavirin treatment for chronic hepatitis C
Olle Reichard, Jan Andersson, Robert Schvarcz et al. · The Lancet · 1991 · 300 citations